{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-104575","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2024-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.076245+00:00","generated_at":"2026-05-31T05:55:30.289570+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prelude Therapeutics Publishes Phase 1 Abstract for PRT3789 SMARCA2 Degrader at ESMO 2024","bullets":["Abstract details first clinical data for PRT3789, a first-in-class IV SMARCA2 degrader in SMARCA4-mutated advanced solid tumors.","As of March 7, 2024, 40 patients enrolled across 6 dose levels (24-212 mg); no DLTs or study-drug-related SAEs reported.","Dose-dependent decreases in SMARCA2 levels observed; RECIST partial responses and tumor shrinkage noted in heavily pretreated NSCLC and esophageal cancer.","Company will host investor webcast on September 13, 2024 at 12:00 PM EST following oral presentation at ESMO Congress."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-104575","json":"https://secwatch.observer/filing/0000950170-24-104575.json","markdown":"https://secwatch.observer/filing/0000950170-24-104575.md","text":"https://secwatch.observer/filing/0000950170-24-104575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024104575/0000950170-24-104575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024104575/prld-20240909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:55:30.289570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}